Corrigendum: ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway

Front Pharmacol. 2021 Nov 18:12:789192. doi: 10.3389/fphar.2021.789192. eCollection 2021.

Yu-Li Shen^{1

2}, Yi-Ping Jiang³, Xiao-Qin Li^{1

4}, Su-Juan Wang⁵, Ming-Hua Ma⁶, Chun-Yan Zhang⁷, Jian-Yong Zhu⁷, Khalid Rahman⁸, Li-Jun Zhang¹, Xin Luan^{1

2}, Hong Zhang¹

¹ Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
² Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
³ Department of Pharmacognosy, School of Pharmacy, Second Military Medical University, Shanghai, China.
⁴ School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
⁵ Department of Drug Preparation, Hospital of TCM and Hui Nationality Medicine, Ningxia Medical University, Wuzhong, China.
⁶ Department of Pharmacy, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China.
⁷ Central Laboratory, Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
⁸ School of Pharmacy and Biomolecular Sciences, Faculty of Science, Liverpool John Moores University, Liverpool, United Kingdom.

Abstract

[This corrects the article DOI: 10.3389/fphar.2019.01596.].

Keywords: JAK/STAT3; diabetic nephropathy; erhuang formula; mechanism; renal fibrosis.